Welcome to our dedicated page for CLOROX CO /DE/ SEC filings (Ticker: CLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CLOROX CO /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CLOROX CO /DE/'s regulatory disclosures and financial reporting.
Clorox executive Stacey Grier reported a small, routine share disposition tied to taxes rather than a market trade. On vesting of restricted stock, the company withheld 32 shares of common stock at a value of $108.73 per share to cover tax obligations.
After this tax-withholding disposition, Grier directly holds 32,116 Clorox shares. This total includes 10 shares acquired through a dividend reinvestment feature of the company’s stock incentive plan, indicating the filing reflects compensation and administrative activity rather than an open-market sale.
The Clorox Company entered into two new unsecured credit facilities totaling $2.25 billion to support its planned acquisition of GOJO Industries, maker of PURELL, and for general corporate purposes.
The first is a $1.0 billion 364-day revolving credit agreement available in U.S. dollars for general corporate use. Borrowings are available until March 5, 2027, and Clorox may convert outstanding amounts into a term loan maturing March 5, 2028. Pricing is based on either a base rate or Term SOFR plus a margin tied to Clorox’s senior unsecured credit rating, and a quarterly facility fee also varies with that rating.
The second is a $1.25 billion delayed draw term credit agreement available at the closing of the GOJO acquisition to finance part of the purchase price, pay related fees and expenses, and repay certain GOJO debt, with any remaining amounts available for general corporate purposes. Loans under this facility mature on March 5, 2027, and undrawn commitments terminate on the earliest of December 31, 2026, termination of the acquisition agreement, or closing of the acquisition without using this financing. Both agreements include customary covenants and events of default, with a consolidated interest coverage ratio as the sole financial covenant and mandatory reductions or prepayments from certain future debt or equity proceeds.
The Clorox Company reported softer results for the quarter ended December 31, 2025. Net sales slipped to $1.67 billion, down 1% from a year ago, as lower consumption in several U.S. categories offset growth internationally. Gross profit was $722 million, with gross margin easing to 43.2% from 43.8% on higher manufacturing and logistics costs despite ongoing cost savings.
Net earnings attributable to Clorox fell to $157 million from $193 million, and diluted EPS declined 16% to $1.29, reflecting lower gross profit and lapping prior-period cyberattack insurance recoveries and tax benefits. For the first six months, net sales decreased 10% to $3.10 billion and diluted EPS dropped 18% to $1.93, pressured by lower shipments following last year’s ERP-related inventory build and the divestiture of the Better Health VMS business.
Operating cash flow remained solid at $404 million for the six-month period. Clorox plans two significant cash uses: a $476 million purchase of Procter & Gamble’s 20% interest in the Glad venture and a definitive agreement to acquire GOJO Industries for approximately $2.25 billion in cash, to be funded primarily with debt, subject to regulatory approval and customary closing conditions.
The Clorox Company filed a current report to note that it issued a press release with its financial results for the second quarter ended December 31, 2025. The press release is provided as Exhibit 99.1, and additional supplemental financial information is included as Exhibit 99.2.
The Clorox Company plans to acquire GOJO, maker of PURELL, by purchasing all of GOJO’s membership interests for $2.25 billion in cash, subject to customary adjustments and including anticipated tax benefits valued at approximately $330 million. Clorox expects to fund the deal primarily with debt financing, and completion will depend on regulatory approval and other customary closing conditions.
Alongside the transaction announcement, Clorox posted an investor presentation and issued a press release that reaffirms its fiscal 2026 outlook for net sales, diluted EPS and adjusted EPS. The company also outlines numerous risks and uncertainties that could affect the closing of the acquisition, integration of GOJO and the expected financial and strategic benefits.
The Clorox Company director reports new deferred stock units tied to CLX common stock. A Form 4 filing shows acquisitions of derivative securities classified as deferred stock units on several 2025 dates. These units convert into Clorox common stock on a 1-for-1 basis.
The director acquired 227.0333 deferred stock units on 11/06/2025 and additional amounts of 1,637.8577 and 272.7363 deferred stock units on 12/31/2025, all at a price of $0.0000 per unit. Following these transactions, the director directly beneficially owns 21,596.5756 deferred stock units.
The filing explains that some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, some represent an annual award under the 2005 Stock Incentive Plan, and others reflect electing to receive quarterly director fees in deferred stock units. These units will be settled entirely in Clorox stock when the director retires or otherwise leaves the board.
Clorox Company director equity compensation and fee deferral is reported in this insider trading disclosure. The filing shows several awards of deferred stock units, each representing the right to receive an equal number of Clorox common shares.
On 11/06/2025, the director acquired 179.1424 deferred stock units at an exercise price of $0.0000, bringing the balance to 15,533.383 units held directly. On 12/31/2025, the director acquired an additional 1,637.8577 deferred stock units and a further 334.7218 units, increasing direct holdings to about 17,505.9625 deferred stock units.
The disclosure notes that some units were obtained through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, others as the annual deferred stock unit award under the 2005 Stock Incentive Plan, and others received instead of quarterly director cash fees. The units will be settled 100% in Clorox stock upon the director’s retirement or other termination of board service.
The Clorox Company director reports additional deferred stock units related to board compensation and dividend reinvestment. On November 6, 2025, the director acquired 199.1684 deferred stock units, each convertible into one share of Clorox common stock, at a price of $0.0000 per unit, bringing the total beneficially owned to 17,269.8302 units.
On December 31, 2025, the director received an additional 1,637.8577 deferred stock units as an annual award and 520.6784 deferred stock units in lieu of quarterly director fees, increasing total holdings to 19,428.3663 deferred stock units. These units are credited under Clorox’s independent director compensation plans and will be settled in Clorox stock when the director retires or otherwise leaves the board.
The Clorox Company director reported several deferred stock unit transactions. On 11/06/2025, the director acquired 63.1574 deferred stock units through dividend reinvestment under the Independent Directors' Deferred Compensation Plan on a 1-for-1 basis with Clorox common stock. On 12/31/2025, the director received 1,637.8577 deferred stock units as an annual award under the 2005 Stock Incentive Plan, and 272.7363 deferred stock units in lieu of quarterly director fees. All units have an exercise price of $0.0000 and each unit represents one share of Clorox common stock. Following these transactions, the director beneficially owns 7,386.9498 deferred stock units, which will be settled in Clorox stock upon retirement or other termination of service as a director.
Clorox Co. (CLX) disclosed a Form 4 for a director reporting routine deferred stock unit activity during 2025. The filing shows multiple acquisitions of deferred stock units tied to Clorox common stock, including 74.9914 units on 02/14/2025, 82.9936 on 05/09/2025, 97.043 on 08/29/2025, 109.0592 on 11/06/2025, and an annual award of 1,637.8577 units on 12/31/2025, all at a price of $0.0000.
After these transactions, the director beneficially owns 11,094.3468 deferred stock units directly. The units are credited on a 1-for-1 basis and will be settled 100% in Clorox stock in connection with the director’s retirement or other termination of service. Some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, and the year-end grant was made under the 2005 Stock Incentive Plan.